Year-end Sale % OFF 
Abstract
The paradigm for the treatment of metastatic colorectal cancer (mCRC) has shown great advances in recent years. With the increasing use of targeted therapies, including epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor (VEGF) antibody, the median overall survival (OS) of mCRC has been raised to approximately 30 months over the last 10 years [1]. Hence, for patients whose tumors are RAS wild-type, anti-EGFR monoclonal antibodies (cetuximab, panitumumab) have shown clinical efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
